RemeGen Co., Ltd. (9995.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Jian Min Fang
Listed since: Nov 9, 2020
Employees: 3,048

Market position

Day range

Current HK$75.20

HK$75.00HK$79.70

52-week range

Current HK$75.20

HK$63.30HK$126.6

Open: HK$79.65
Previous close: HK$78.90
Volume: 2.22M; 0.5× average
Average volume: 4.43M; Average daily volume
Market cap: 41.62B HKD
Beta: 0.45; Market reference 1
50-day average: HK$79.456; -5.36% below average
200-day average: HK$86.084; -12.64% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 36.53B CNY
P/E (TTM): 51.57×
P/B (TTM): 16.74×
P/S (TTM): 19.25×
EV / EBITDA: 84.6×
Earnings yield: 2.00%
Free cash flow yield: -0.39%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 85.40%
Operating margin: 9.06%
Net margin: 38.17%
Return on equity: 19.66%
Return on assets: 9.79%
Return on invested capital: 2.64%

Financial health

Debt / equity: 0.53×
Current ratio: 1.43×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

3.24B CNY+88.81%

Operating income

156.35M CNY+1.61B CNY

Net income

709.65M CNY+2.18B CNY

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	3.24B CNY	1.72B CNY	1.08B CNY	767.78M CNY	1.42B CNY
Cost of goods sold	415.49M CNY	346.72M CNY	253.14M CNY	269.94M CNY	67.16M CNY
Gross profit	2.84B CNY	1.37B CNY	822.99M CNY	497.84M CNY	1.36B CNY
Research and development	1.08B CNY	1.56B CNY	1.31B CNY	982.08M CNY	710.97M CNY
Selling, general, and administrative	1.48B CNY	1.28B CNY	1.09B CNY	713.24M CNY	482.81M CNY
Operating expenses	2.11B CNY	2.83B CNY	2.33B CNY	1.55B CNY	1.05B CNY
Interest income	4.89M CNY	10.24M CNY	28.14M CNY	61.54M CNY	43.35M CNY
Interest expense	68.53M CNY	72.38M CNY	23.09M CNY	6.76M CNY	5.32M CNY
Depreciation and amortization	312.05M CNY	231.01M CNY	240.28M CNY	186.37M CNY	120.47M CNY
Operating income	156.35M CNY	−1.46B CNY	−1.5B CNY	−1.05B CNY	162.84M CNY
Net income	709.65M CNY	−1.47B CNY	−1.51B CNY	−997.84M CNY	276.26M CNY